Comparison of efficacy and tolerability of hedgehog pathway inhibitors for locally advanced basal cell carcinoma: An expert opinion in the new age of immunotherapy. (PubMed, J Am Acad Dermatol) - Oct 9, 2026 - "Both vismodegib and sonidegib remain essential tools in the management of advanced BCC. Understanding their pharmacologic and clinical differences enables more personalized treatment planning, enhancing long-term outcomes and expanding their use in neoadjuvant and maintenance settings."
Journal • Review • Basal Cell Carcinoma • Non-melanoma Skin Cancer • Oncology
|
|
Kennedy H Sun; Marcus Tan; Michael R Migden; Sarah H Millan; Vishal A Patel
|